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Abstract
Recently, an improved understanding of the molecular mechanisms governing
the host response to tumors has led to the identiﬁcation of checkpoint signaling
pathways involved in limiting the anticancer immune response. One of the
most critical checkpoint pathways responsible for mediating tumor-induced
immune suppression is the programmed death-1 (PD-1) pathway, normally
involved in promoting tolerance and preventing tissue damage in settings of
chronic inﬂammation. Many human solid tumors express PD ligand 1 (PD-
L1), and this is often associated with a worse prognosis. Tumor-inﬁltrating
lymphocytes from patients with cancer typically express PD-1 and have
impaired antitumor functionality. Proof-of-concept has come from several pre-
clinical studies in which blockade of PD-1 or PD-L1 enhanced T-cell function
and tumor cell lysis. Three monoclonal antibodies against PD-1, and one
against PD-L1, have reported phase 1 data. All four agents have shown encour-
aging preliminary activity, and those that have been evaluated in larger patient
populations appear to have encouraging safety proﬁles. Additional data are
eagerly awaited. This review summarizes emerging clinical data and potential of
PD-1 pathway–targeted antibodies in development. If subsequent investigations
conﬁrm the initial results, it is conceivable that agents blocking the PD-1/PD-L1
pathway will prove valuable additions to the growing armamentarium of tar-
geted immunotherapeutic agents.
Introduction
Multiple immunotherapeutic approaches to cancer treat-
ment have been evaluated over the past several decades.
Although the results of many of these early efforts have
been disappointing, the ability to produce durable remis-
sions of solid tumors with high-dose interleukin-2 (HD
IL-2), interferon-a, and vaccines has nevertheless provided
evidence of immunotherapy’s potential [1–3]. Recent data
have provided a clearer understanding of the factors that
limit an antitumor immune response, leading to the
development of various agents targeting immune costimu-
latory and inhibitory (“checkpoint”) pathways. One of the
key checkpoint molecules that mediates tumor-induced
immune suppression is programmed death-1 (PD-1).
Traditional costimulation is delivered by the signaling
of antigen-presenting cell (APC) CD80/86 through T-cell
CD28, the so-called “second signal” required for T-cell
activation. In addition to CD28, other immune costimu-
latory molecules include inducible costimulator [4],
CD137 (also known as 4-1BB), and OX40 [5]. Conversely,
several negative regulatory checkpoint molecules function
to prevent, or “check,” overstimulation of immune
responses and contribute to the maintenance of immune
tolerance to self-antigens [6]. These molecules include
cytotoxic T-lymphocyte antigen-4 (CTLA-4) as well as the
PD-1 receptor and its ligands. CTLA-4 acts as a signal
dampener that acts largely within the lymph nodes to reg-
ulate the magnitude of early activation of na€ ıve and
memory T cells. PD-1, by contrast, is induced on T cells
after activation in response to inﬂammatory signals and
limits T-cell function in various peripheral tissues, largely
in the context of infection or tumor progression [7]. As
the T-cell response builds, these negative regulatory mole-
cules are induced, limiting the magnitude and duration of
the response to prevent healthy tissue damage.
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mechanisms regulated by these checkpoint molecules.
They can overwhelm the immune system via multiple
strategies, including alterations in antigen expression,
interference with T-cell priming, and a spectrum of effects
referred to as “immune editing,” whereby tumors manip-
ulate their microenvironment during development to
escape immune detection and eradication [8]. Limiting
antitumor T-cell responses via exploitation of checkpoint
pathways (such as those involving CTLA-4 or PD-1)
serves to prevent signiﬁcant tumor destruction and leads
to an equilibrium between the tumor and immune system
that typically progresses to tumor escape. New immuno-
therapies for cancer focus on shifting the balance from a
pro-tumor to an antitumor microenvironment, thus
allowing the immune system to mount an effective antitu-
mor response; consequently, negative regulatory pathways
are key targets. The anti–CTLA-4 monoclonal antibody
(mAb) ipilimumab improved survival in a phase 3 trial in
patients with metastatic melanoma (MEL) [9] and was
subsequently approved by the United States Food and
Drug Administration for the treatment of patients with
advanced MEL. A recent report of an early-stage trial has
provided preliminary evidence of activity of ipilimumab
in patients with castrate-resistant prostate cancer (CRPC)
[10]. The fully human anti–PD-1 mAb BMS-936558/
MDX-1106/ONO-4538 (nivolumab), tested in renal cell
cancer (RCC), MEL, CRPC, non–small cell lung cancer
(NSCLC), and colorectal cancer (CRC), has demon-
strated antitumor activity in phase 1/1b studies [11]. The
humanized anti–PD-1 antibody MK-3945 (lamb-
rolizumab) has also demonstrated antitumor activity in
patients with solid cancers in a phase 1 study [12]. CT-
011 (pidilizumab), a humanized anti–PD-1 antibody, has
been evaluated in multiple hematologic malignancies,
demonstrating potential clinical activity in patients with
non-Hodgkin’s lymphoma, chronic lymphocytic leukemia,
Hodgkin’s lymphoma, multiple myeloma, and acute mye-
loid leukemia [13]. Finally, the anti–PD ligand 1 (PD-L1)
mAb BMS-936559 has shown preliminary antitumor
activity in various solid cancers [14]. PD-1 pathway–
targeted agents in development are summarized in Table 1.
This review examines the role of the PD-1 negative regu-
latory pathway in antitumor immune responses and out-
lines the rationale for targeting PD-1 and PD-L1 in the
treatment of patients with cancer.
Role of the PD-1 Pathway in the
Immune Response
PD-1 (CD279), a member of the B7-CD28 family [15], is
a cell surface coinhibitory receptor expressed on T cells, B
cells, monocytes, and natural killer T cells, following acti-
vation [16]. PD-1 has two known ligands: PD-L1 (B7-
H1) [17] and PD-L2 (B7-DC) [18], which have distinct
expression proﬁles. Both ligands are expressed on APCs,
including dendritic cells (DCs); in addition, PD-L1,
thought to be the principal mediator of PD-1-dependent
immunosuppression [19], is expressed on some non-
hematopoietic cells. Binding of PD-L1 or PD-L2 to PD-1
inhibits T-cell receptor signaling and downregulates the
expression of certain antiapoptotic molecules (including
B-cell lymphoma-extra large [Bcl-xL]) and proinﬂamma-
tory cytokines [16]. The interaction of PD-1 with its
ligands also affects the cell cycle, preventing progression
through G1 phase by increasing expression levels of p15
and suppressing transcription of SKP2, a component of
the ubiquitin ligase responsible for degrading p27 [20].
PD-L1 itself has also been observed to serve as an anti-
apoptotic factor on tumor cells [21]. Interestingly, PD-L1
expressed on APCs can also bind T-cell CD80, which
curtails T-cell activation and cytokine production. The
PD-1 pathway is an important regulator of the induction
and maintenance of peripheral tolerance (and tolerance to
malignant “self” cells within the tumor microenviron-
ment) [22, 23], by upholding a balance between T-cell
activation and the protection of healthy tissues from
immune-mediated damage.
The critical role of the PD-1 pathway in blunting T-cell
responses was ﬁrst demonstrated by the various autoim-
mune phenotypes observed in PD-1 knockout mice [16].
In addition, PD-L1 expression on nonhematopoietic cells
was shown to inhibit immune-mediated tissue damage
[21, 24]. The PD-1/PD-L1 pathway also participates in
Table 1. PD-1 pathway–targeted agents in development.
Target Name Description Sponsor Phase
PD-1 Nivolumab Fully human IgG4 monoclonal antibody Bristol-Myers Squibb 3
Lambrolizumab Humanized IgG4 monoclonal antibody Merck 3
Pidilizumab Humanized IgG1 monoclonal antibody CureTech 2
AMP-224 B7-DC/IgG1 fusion protein GlaxoSmithKline/Amplimmune 1
PD-L1 BMS-936559 Fully human IgG4 monoclonal antibody Bristol-Myers Squibb 1
RG7446/MPDL3280A Monoclonal antibody Roche/Genentech 1
MEDI4736 Monoclonal antibody MedImmune 1
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tent T-cell activation in the setting of chronic infection
produces sustained, high-level PD-1 expression and
results in functionally exhausted T cells. Such T cells are
unable to proliferate and destroy invading microorgan-
isms, thus allowing infections to persist; however, this
inactivity of T cells also reduces collateral immune-related
damage to host cells [25]. Cancers exploit multiple
immunoregulatory pathways to evade elimination by inﬁl-
trating, activated tumor-speciﬁc T cells, including the
production of immunosuppressive cytokines (transform-
ing growth factor-b [TGF-b], interleukin-10 [IL-10]), the
expression of immunosuppressive enzymes (indoleamine-
2,3-dioxygenase), and the conversion of “normal” APCs
and T cells to immunosuppressive cell populations (e.g.,
regulatory T cells) [26]. Similarly, tumor upregulation of
PD-L1 expression, commonly induced by inﬁltrating
T-cell release of interferon-c (IFN-c) [27], leads to inacti-
vation of T cells expressing PD-1, further enabling tumor
cell evasion of immune destruction (Fig. 1).
Role of the PD-1 Pathway in Cancer
Gajewski and colleagues have recently observed that
certain tumors exhibit an “inﬂammatory” gene signature,
suggesting the existence of an ongoing immune response;
moreover, patients with “inﬂamed” tumors appear to
respond better to immunotherapy. Intriguingly (and per-
haps counter-intuitively), “inﬂamed” tumors contained
higher expression levels of the immunosuppressive mole-
cules PD-L1, FoxP3 (the transcription factor controlling
regulatory T-cell [Treg] development) and indoleamine-
2,3-dioxygenase (an enzyme critically involved in periph-
eral tolerance) [28]. The PD-1 pathway, therefore, may
have a key role in the interaction of tumor cells with the
host immune response, and tumor cell PD-L1 expression
may serve as a mechanism of adaptive immune resistance.
Expression of PD-1 by tumor-inﬁltrating lymphocytes
(TILs) is associated with impaired effector function (cyto-
kine production and cytotoxic efﬁcacy against tumor
cells) and/or poor outcome in several tumor types [29–
32]. Moreover, a variety of tumors, including RCC, MEL,
as well as stomach, breast, ovarian, pancreatic, and lung
cancers, have been shown to express PD-L1, potentially
contributing to immune suppression and evasion [33]. Of
note, PD-L1 expression on tumor cells has been shown to
correlate with poor prognosis in patients with RCC
(Fig. 2) [34], MEL, and breast, pancreatic, stomach,
bladder, lung, liver, and ovarian cancers (Table 2) [33,
35–38]. However, a recent report has shown that not all
or or or
AB C
Figure 1. PD-1 in T-cell activation, exhaustion, and effector function. (A) T cells are activated via (1) binding of MHC plus peptide on an APC to
the TCR and then (2) binding of APC CD80/86 to T-cell CD28. In patients with cancer, tumor cells can also serve as APCs. Upon T-cell activation,
PD-1 expression is induced. (B) In situations of chronic infection or persistent stimulation, PD-L1 signals through T-cell PD-1 to “turn off” T cells in
order to minimize damage to healthy tissue. Tumor cells can upregulate PD-L1 in order to “turn off” T cells that might destroy them. (C) Blocking
the PD-1/PD-L1 signaling pathway allows T cells to maintain their effector functions. In patients with cancer, activated tumor-speciﬁc T cells can
kill tumor cells and secrete cytokines that activate/recruit other immune cells to participate in the antitumor response. APC, antigen-presenting
cell; IFN-c, interferon gamma; MHC, major histocompatibility complex; PD-1, programmed death-1; PD-L1, PD ligand 1; TCR, T-cell receptor.
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In this study, patients with PD-L1
+ MEL survived signiﬁ-
cantly longer than patients with PD-L1
 MEL, spurring
investigators to hypothesize that TILs may actually
prompt their own inhibition by secreting cytokines (such
as IFN-c) that drive tumor PD-L1 expression. However,
because of the signiﬁcant number of patients who
received subsequent immune-based therapies, care must
be taken interpreting these data. It is, however, possible
that induction of the PD-L1/PD-1 pathway represents a
mechanism of adaptive resistance exerted by tumors inﬁl-
trated by effector T cells, and is therefore a marker of an
ongoing antitumor immune response. Similarly, PD-L2
has been observed to be upregulated in a subset of human
tumors and has occasionally been linked to poor outcome
[39]. Consequently, therapies that block the PD-1 path-
way may unleash antitumor immunity and be particularly
beneﬁcial to patients with PD-L
+ tumors.
Ahmadzadeh and colleagues showed that PD-1 expres-
sion on TILs in MEL lesions was signiﬁcantly higher than
expression on T cells isolated from the peripheral blood
(PB) or noncancerous tissue from the same patients or
healthy donors [31]. In this study, PD-1
+ TILs had
impaired effector function, as measured by IFN-c secre-
tion, indicating that PD-1 expression on TILs limits their
capacity to mount an effective immune response. Patients
with MEL also have higher levels of PD-1 expression on
TILs than on PB lymphocytes [40]. In addition, blockade
of the PD-1/PD-L1 pathway increased IFN-c secretion by
T cells in response to stimulation by antigen-loaded DCs.
Overall, these ﬁndings suggest that inhibition of the
PD-1/PD-L1 pathway can restore effector functions of
exhausted T cells, which may translate into improved
antitumor immune responses. Thus, the PD-1/PD-L1
pathway represents a logical target for cancer immuno-
therapy.
Preclinical Studies of PD-1 Blockade
Blockade of either PD-1 or its ligands has shown consis-
tent immune-potentiating effects in a range of preclinical
models. Antibodies against PD-1 or PD-L1 can enhance
or restore T-cell effector function, including cytolytic
activity against tumor cells [40–42]. Moreover, PD-L1
blockade promoted inﬁltration of tumor-reactive CD8+ T
cells into established tumors in a mouse model of pancre-
atic cancer [43], while PD-L2 blockade decreased the
numbers of tumor-inﬁltrating regulatory T cells [44]. PD-
1 blockade inhibited the metastatic spread of MEL and
colon cancer cells in mice [45]. Experiments in mice lack-
ing PD-1 showed that hematogenous tumor spread
was inhibited via several T-cell potentiating mechanisms,
including enhanced induction of effector T cells in the
spleen, augmented homing of these cells to tumor sites,
and improved T-cell proliferation and cytotoxicity [45].
Several preclinical studies have shown that PD-1 or
PD-L1 blockade improves the immune response to, and/
or efﬁcacy of, other immunotherapies, including anti–
CTLA-4 mAbs [41–43, 46]. PD-L1 inhibition was also
synergistic with chemotherapy in a mouse model of pan-
creatic cancer [43]. These observations have important
implications for the development of potential combina-
tion treatment strategies for patients with cancer.
Clinical Studies Investigating
PD-1/PD-L1 Blockade
Because of the varied negative signals resulting from
interactions between PD-1/PD-L1/PD-L2 and PD-L1/
CD80, there are opportunities to target this checkpoint
pathway from two directions: PD-1 blockade inhibits
Table 2. PD-L1 expression and clinical outcomes in cancer.
Disease PD-L1 expression associations
RCC Poor prognosis [30]
NSCLC Decreased survival [35]
MEL Increased [24] or decreased [32] survival
Breast Tumor size, stage, and HER2 expression [30]
Gastric Tumor size, metastasis, and poor survival [30]
Ovarian Poor prognosis [30]
Pancreatic Decreased TILs and poor prognosis [30]
HCC (HBV related) Poor postcryoablation prognosis
1 [33]
HCC Tumor aggressiveness and recurrence
after resection [34]
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; MEL, mela-
noma; NSCLC, non–small cell lung cancer; RCC, renal cell cancer.
1Associated with PD-L1 expression on circulating leukocytes.
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Figure 2. Increased PD-L1 expression (≥10% vs. <10%) diminishes
survival in RCC. From Thompson et al. [34]. Copyright 2012 National
Academy of Sciences, U.S.A. Reprinted with permission.
ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 665
D. F. McDermott & M. B. Atkins Targeting PD-1 in Cancer Therapynegative signaling induced by PD-L1 and PD-L2 ligation,
whereas PD-L1 blockade inhibits negative signaling via
PD-1 and CD80. MAbs that target these interactions
are being evaluated in clinical studies and hold promise
as an important immunotherapeutic approach in various
malignancies. Data from clinical trials targeting the inter-
actions between PD-1 and its ligands have recently
become available.
PD-1 Blockade with Anti–PD-1
Antibodies
Nivolumab
The ﬁrst phase 1 trial of varying doses (0.3–10 mg/kg) of
nivolumab, a fully human IgG4 anti–PD-1-blocking anti-
body, in 39 patients with advanced MEL, CRC, CRPC,
NSCLC, or RCC was reported in 2010 [19]. One com-
plete response (CR) (CRC 3 mg/kg) (21+ months at last
follow-up) and two partial responses (PRs) (RCC and
MEL [both 10 mg/kg]) were observed. No maximum
tolerated dose (MTD) was identiﬁed. Most adverse
events (AEs) reported for nivolumab were immune-
related, consistent with the mechanism of action of
anti–PD-1 antibodies. Flow cytometric analysis showed
sustained occupancy of the majority of PD-1 molecules
on circulating T cells isolated from patient plasma sam-
ples for ≥3 months following a single dose of nivolumab.
In an expansion cohort at the 10-mg/kg dose level,
responses were seen in patients with MEL and RCC with-
out increased toxicity. One patient with RCC who had
received several prior therapies achieved a PR that lasted
16+ months despite receiving only three nivolumab infu-
sions. Additionally, two patients (NSCLC, MEL) achieved
signiﬁcant regression of metastatic lesions that did not
meet PR criteria [19]. Follow-up of three patients from
this study has demonstrated long-term responses after
discontinuation of therapy [47].
The activity seen in the initial study prompted an
exploration of a biweekly schedule of nivolumab in a sep-
arate phase 1 trial [11, 48]. Interim data from 304
patients with RCC, MEL, CRPC, NSCLC, or CRC who
received 0.1 mg/kg to 10 mg/kg nivolumab every 2 weeks
in 8-week cycles have recently been reported. Patients
received treatment (≤12 cycles) until they experienced CR
or progressive disease. Of 294 response-evaluable patients,
there were objective responses (ORs) in 20/122 patients
with NSCLC, 33/106 patients with MEL, and 10/34
patients with RCC. No ORs were noted in patients with
CRPC or CRC. At last follow-up, 28 patients to date have
had responses lasting ≥1 year. Stable disease (SD) lasting
24+ weeks was observed in an additional six evaluable
patients with MEL, 11 with NSCLC, and nine with RCC.
Additional patients with each disease experienced tumor
responses to nivolumab according to immune-related
response criteria; one pattern is typiﬁed by an initial
increase and then decrease in tumor size (Fig. 3).
Antitumor activity was observed at 1- to 10-mg/kg dose
levels; some patients appeared to continue to exhibit
tumor response beyond 96 weeks, the protocol-deﬁned
treatment stoppage point. The most common treatment-
related AEs included fatigue, rash, nausea, diarrhea,
decreased appetite, and pruritus. Grade 3/4 treatment-
related AEs occurred in 15% of patients, and there were
three deaths, all attributed to pulmonary toxicity.
Drug-related AEs of special interest (AEOSIs, AEs with
potentially immune-related etiology) included vitiligo,
pneumonitis, hepatitis, colitis, thyroiditis, and hypophysi-
tis. Should this preliminary efﬁcacy and relatively favor-
able toxicity proﬁle be conﬁrmed in future trials, PD-1
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Figure 3. Durable responses in a cohort of
patients with MEL treated with 1 mg/kg
nivolumab. From Topalian et al. [11]. Copyright
2012 Massachusetts Medical Society. Reprinted
with permission.
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a durable beneﬁt with fewer toxicities than with other im-
munotherapies (e.g., HD IL-2 or ipilimumab). Nivolumab
is currently being evaluated in several ongoing clinical
trials of patients with RCC, MEL, and various other
malignancies (clinicaltrials.gov).
Pidilizumab
The humanized, anti–PD-1 mAb pidilizumab was
evaluated in a phase 1 clinical trial of patients with
advanced hematologic malignancies [13]. Seventeen
patients received escalating doses of pidilizumab ranging
from 0.2 to 6 mg/kg. Treatment with pidilizumab gener-
ally was well tolerated, and no MTD was deﬁned. Only
one patient reported toxicity, speciﬁcally weakness, and
ﬂushing, which were possibly treatment related. Clinical
beneﬁt was observed in 33% of patients. An apparent
response to treatment was observed in six patients,
including one CR, four SD, and one mixed response; the
CR was maintained for ≥68 weeks. Sustained elevation in
PB CD4
+ lymphocyte numbers was observed up to
21 days following treatment with pidilizumab [13]. The
activity of pidilizumab in solid tumors is now being
explored (clinicaltrials.gov).
Lambrolizumab
Patnaik and colleagues reported the results of a small,
open-label dose-escalation study examining lamb-
rolizumab, a humanized IgG4 mAb against PD-1 [12].
Cohorts of three to six patients with various advanced
solid tumors were treated with 1–10 mg/kg initially and
then additional doses every 2 weeks. No MTD was identi-
ﬁed, and there were no grade ≥3 drug-related AEs; one
patient developed pneumonitis, which was treated with
corticosteroids. Two patients with MEL treated for 6+
months had PRs, and there was an unconﬁrmed PR in a
patient with squamous NSCLC. In the MEL expansion
cohort treated with 10 mg/kg, one unconﬁrmed CR, three
unconﬁrmed PRs, and ﬁve grade 3/4 AEs were reported
(NCT01295827) [12]. Additional interim data on 85
evaluable patients were recently presented at the Society
for Melanoma Research Congress [49], Forty-three
patients (51%) experienced ORs, including eight CRs. 27
patients had previously been treated with ipilimumab and
11 of these (41%) had ORs. Seven treatment-related grade
3/4 AEs with potentially immune-mediated causes were
reported. There were three instances of grade 1/2 pneu-
monitis; one patient died of myocardial infarction while
being treated for pneumonitis/pneumonia. Common AEs
included arthralgia, cough, diarrhea, fatigue, fever, nausea,
pruritus, and rash.
Patterns of response to PD-1 blockade
While a subset of melanoma and lung cancer patients
treated with PD-1-pathway–targeted agents have experi-
enced encouraging ORs, fewer have experienced SD. It is
possible that the response to PD-1 pathway blockade is
“all or nothing.” In comparison, while only a small per-
centage of patients treated with ipilimumab achieve ORs,
this agent improved median OS in phase 3 trials, suggest-
ing a clinical beneﬁt in patients who did not meet
response criteria [9, 50]. It is possible that PD-1-path-
way–directed agents may impart a survival beneﬁt only to
those patients on the “tail” of the survival curve. Whether
these agents will improve median OS in unselected
patients will be determined by ongoing, randomized
phase 3 trials.
It should be noted that select responding patients who
discontinued PD-1 antibody therapy subsequently demon-
strated disease progression, suggesting that the optimal
duration of anti–PD-1 agent dosing may vary from
patient to patient. However, some patients who pro-
gressed after discontinuation of anti–PD-1 therapy have
demonstrated durable responses after retreatment [47].
The optimal duration of PD-1-pathway–targeted agent
treatment is still being determined; if shorter treatment
durations are proven efﬁcacious, this approach would be
more cost-effective. The ultimate beneﬁt of immunothera-
peutics (e.g., IL-2, ipilimumab) is their ability to produce
remissions that are durable when therapy is discontinued.
Although this has been observed in select patients treated
with anti–PD-1 agents, the percentage of patients who
achieve durable remissions remains to be determined.
Nonetheless, the potential beneﬁts for patients who expe-
rience “treatment-free survival” include decreased treat-
ment-associated toxicity, improved quality of life, and
decreased cost to the healthcare system. While this end-
point is not currently standard for approving therapies,
its value to the patient merits consideration in future
studies.
PD-1 Blockade with PD-1 Ligand-
targeted Agents
BMS-936559
Interim data from a phase 1 trial (NCT00729664) of
BMS-936559, an anti–PD-L1 mAb, have recently been
disclosed [14]. As of 24 February 2012, 207 patients (with
NSCLC, MEL, CRC, RCC, and ovarian, pancreatic, or
breast cancer) had received BMS-936559 (at escalating
doses ranging from 0.3 to 10 mg/kg) every 2 weeks in
6-week cycles. This continued for 16 cycles or until pro-
gressive disease or CR; the MTD was not identiﬁed. In
ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 667
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with MEL (9/52), RCC (2/17), NSCLC (5/49), and ovar-
ian cancer (1/17). In the 16 patients with ≥1 year of
follow-up, responses in half lasted for ≥1 year. SD
(≥24 weeks) was observed in 14 patients with MEL, six
patients with NSCLC, three patients with ovarian cancer,
and seven patients with RCC. Most AEs were low grade;
the most common treatment-related AEs included fatigue,
diarrhea, infusion reactions, rash, arthralgia, headache,
nausea, and pruritus. Grade 3/4 treatment-related toxici-
ties occurred in 9% of patients. Thirty-nine percent of
patients experienced AEOSIs, including rash, hepatitis,
hypothyroidism, and one case each of diabetes mellitus,
endophthalmitis, sarcoidosis, and myasthenia gravis. The
data collected to date demonstrate that BMS-936559 has
a relatively good safety proﬁle and can induce durable
responses in patients with MEL, NSCLC, and RCC.
Other agents
Genentech and Roche are evaluating a mAb targeting
PD-L1 (RG7446/MPDL3280A), and Amplimmune and
GlaxoSmithKline have partnered in the development of a
PD-L2/IgG1 fusion protein (AMP-224) that blocks PD-1
signaling. More recently, MedImmune announced that it
would pursue development of the anti–PD-L1 mAb
MEDI4736 [51]. All three of these compounds are cur-
rently in phase 1 testing (clinicaltrials.gov).
Targeting PD-1 versus PD-L1
Without a randomized, head-to-head trial of these drugs,
no conclusive statements can be made regarding the
comparative safety and activity of agents targeting PD-1
versus those targeting PD-L1. It appears, however, that
targeting only PD-L1 may be accompanied by less toxicity,
but also may be less effective than targeting PD-1 and thus
blocking signaling via both PD-L1 and PD-L2.
Differences from anti–CTLA-4 antibodies
The anti–PD-1 data we currently have are from phase 1
trials, and no randomized, head-to-head studies of anti–
PD-1 and anti–CTLA-4 antibodies have been completed.
However, the existence of these agents in the same immu-
notherapeutic category will no doubt prompt compari-
sons. Both PD-1 and CTLA-4 are checkpoint molecules;
however, they participate in different phases of the
immune response. Murine experiments suggest that
CTLA-4 is centrally involved in the development of toler-
ance and the prevention of autoimmunity, while the role
of PD-1 is to prevent bystander tissue damage at sites of
chronic infection and inﬂammation [52–54]. Additionally,
given the body of data on PD-L1 and PD-1 as potential
prognostic and predictive biomarkers, it seems that this
pathway may be more important in the tumor microenvi-
ronment. Preclinical data [46] suggest that the combina-
tion of inhibitors of PD-1 and CTLA-4 may present a
promising approach, which is currently being explored in
the clinical setting [NCT01454102, NCT01024231].
Future Directions
Predictive biomarker development
The correlation between tumor PD-L1 expression and
prognosis supports the hypothesis that this molecule may
serve as a predictive biomarker. Although immune inﬁltra-
tion of antitumor lymphocytes leading to PD-L1 upregula-
tion might establish a scenario predictive of beneﬁt for
any effective immunotherapy, this is particularly true of
agents targeting the PD-1 pathway. As mentioned previ-
ously, expression of PD-1 by TILs is associated with poor
prognosis in multiple cancers [29, 32]. In patients with
RCC, the presence of PD-1
+ TILs was associated with
more aggressive tumors and shortened survival [29]. In
addition, patients with PD-1
+ TILs were more likely than
patients without PD-1
+ TILs to have larger tumors,
tumors of higher nuclear grade, advanced tumor node-
metastasis stage, coagulative tumor necrosis, and sarcoma-
toid differentiation. In RCC and other cancers, tumor
expression of PD-L1 is also associated with poor prognosis
and more aggressive disease [33, 34]. However, the signiﬁ-
cance of PD-L1 expression in the context of active immu-
notherapy, particularly PD-1/PD-L1 pathway blockade, is
less clear. Given that tumor PD-L1 expression is induced
by T-cell expression of IFN-c, it may signify an effort by
the tumor to evade an ongoing immune response. There-
fore, blockade of the PD-1/PD-L1 pathway with an anti–
PD-1 or anti–PD-L1 antibody may enable the unmasking
of antitumor immunity patients with PD-L1
+ tumors. Pre-
liminary data suggesting that tumor PD-L1 expression
could be a predictive biomarker of response to nivolumab
[19] were later supported by an observation that 0/17
nivolumab-treated patients with PD-L1
 tumors experi-
enced ORs, whereas 9/25 patients with PD-L1
+ tumors
(36%) achieved ORs (P = 0.006). If these data are con-
ﬁrmed, PD-L1 positivity may be a way to identify and
enrich the population of patients who beneﬁt from PD-1
pathway–targeted therapy. Further evaluation of PD-L1 as
a potential predictive marker is warranted.
Opportunities for combination therapy
Even at this stage of PD-1–targeted agent development, it
is important to consider opportunities for combination
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induce PD-L1 expression, it may be feasible to treat
patients with these molecules (e.g., IFN-a,- b, and -c
[16]; cisplatin [55]) to induce PD-L1 expression in the
tumor microenvironment and expand the population of
patients who might beneﬁt from treatment with PD-
1-pathway–directed agents. In addition, tumors can evade
detection and destruction by manipulating the immune
system: downregulating costimulatory molecules on
tumor cells, increasing expression of immunosuppressive
molecules, and dysregulating T cells and APCs. Therefore,
the implementation of rational, multiagent treatments
that target distinct pathways may circumvent these tumor
survival strategies.
Dual checkpoint blockade
The combination of CTLA-4 and PD-1 blockade may also
enable more persistent immune activation while avoiding
the major toxicities associated with HD IL-2. Hypotheti-
cally, combining two agents that target T-cell activation
at different stages of the immune response will be a more
potent anticancer treatment than therapy with each agent
alone. Ipilimumab removes a physiological brake on T
cells during activation, whereas anti–PD-1 removes a
brake on activation during T-cell effector function. This
combination may also overcome resistance to CTLA-4
blockade mediated by tumor PD-L1 expression or resis-
tance to PD-1 blockade mediated by T-cell downregula-
tion through the coexpression of CTLA-4. A phase 1 trial
of nivolumab and ipilimumab in patients with MEL is
ongoing (NCT01024231). Another potential checkpoint
combination therapy might include blockade of PD-1 and
LAG-3, a molecule also involved in the regulation of
T-cell activation. Combination therapy in mice has shown
impressive activity [56].
Targeted therapy combinations
The combination of agents that block immune down-
regulation with genetic or cell-targeted therapies may
prove particularly effective in select patients. Following
this line of thought, pidilizumab is being tested in com-
bination with rituximab, an anti-CD20 antibody, in a
phase 2 trial of patients with relapsed follicular lym-
phoma (NCT00904722). The combination of PD-1–tar-
geted therapy with agents effective against genetic
mutations may also demonstrate activity. Trials examin-
ing vemurafenib, an inhibitor of B-raf enzymes with the
V600E mutation, and other BRAF and epidermal growth
factor receptor–targeted agents, in combination with PD-
1 pathway inhibitors are under way (NCT01454102,
NCT01656642). Various chemotherapies are also being
evaluated in combination with anti–PD-1 agents
(NCT00890305, NCT01454102).
T-cell stimulating agent combinations
IL-2 is a cytokine that supports T-cell survival and prolif-
eration. The combination of HD IL-2 and ipilimumab
has demonstrated manageable toxicity and impressive efﬁ-
cacy (CR rate of 17%) in patients with advanced MEL
[57]. Thus, it is conceivable that the combination of HD
IL-2, to induce T-cell expansion, and PD-1 blockade, to
eliminate tumor-induced immune suppression, might
prove equally or more efﬁcacious in select patients.
Vaccine combinations
The PD-1/PD-L1 pathway may play an important role in
blunting immune response to tumor vaccines. Study ﬁnd-
ings suggest that stimulation with dendritic/tumor fusion
cells increases T-cell expression of PD-1, which may blunt
the host response to vaccination [58]. In ex vivo studies,
stimulation of T cells with a DC/tumor fusion vaccine in
the presence of PD-1 blockade resulted in increased cyto-
kine production, decreased Tregs, and enhanced tumor
killing [58]. As such, combining DC-based tumor vac-
cines with PD-1 blockade may be an effective means of
enhancing immunologic and clinical response to vaccina-
tion. Interestingly, two trials evaluating the efﬁcacy of
nivolumab in combination with multipeptide melanoma
vaccines are ongoing (NCT01176474, NCT01176461).
Thus far, conﬁrmed PRs have been reported in patients
with unresectable melanoma at each of the treating dose
levels (two at 1 mg/kg, four at 3 mg/kg, and one at
10 mg/kg), and the most common drug-related AEs are
low-grade injection site reactions and nausea/vomiting
[59]. Pidilizumab is being tested in combination with DC
fusion vaccines in patients with multiple myeloma after
stem cell transplantation (NCT01067287), patients with
RCC (NCT01441765), and patients with acute myeloid
leukemia (NCT01096602).
VEGFR tyrosine kinase inhibitor (TKI)
combinations
The anti–CTLA-4 mAb tremelimumab administered with
the vascular endothelial growth factor receptor (VEGFR)
TKI sunitinib produced PRs in 9/21 evaluable patients
with RCC, but was associated with acute renal toxicity,
which the authors proposed might be immune related
[60]. It is conceivable that combinations involving
VEGFR TKIs with PD-1/PD-L1 pathway blockade may be
better tolerated. Thus, an ongoing trial is assessing the
safety and tolerability of nivolumab when administered
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(NCT01472081) [61].
VEGF-targeted agent combinations
There is evidence that VEGF decreases DC function [62],
and by extension, antigen presentation and T-cell activa-
tion. Concurrently restoring DC and T-cell functionality
may improve the antitumor T-cell response and lead to
improved clinical activity. As proof-of-concept, Hodi and
colleagues have observed durable PRs in patients with
MEL treated with a combination of ipilimumab and the
anti–VEGF-A antibody bevacizumab [63]. Trials evaluat-
ing the combination of nivolumab (NCT01454102) or
ipilimumab (NCT00790010) with bevacizumab are on-
going (clinicaltrials.gov).
Various beneﬁts and drawbacks accompany the use of
broad spectrum versus more speciﬁc VEGF inhibitors.
Broad-spectrum agents are indeed pleiotropic and, among
various “off-target effects” can impact immune system
function. For instance, murine experiments have shown
that sunitinib can decrease Treg populations [64]; other
TKIs are associated with immune system-potentiating
effects [65]. If the pleiotropic effects of a given VEGFR
TKI have a net positive effect on the immune system and
are not overwhelmingly detrimental to other physiological
processes, it may indeed be worth exploring in combina-
tion with anti–PD-1-pathway–directed agents. In contrast,
VEGF-targeted agents like bevacizumab and VEGF-trap
are more speciﬁc in their inhibition, but are not typically
accompanied by immune-potentiating effects. As high
levels of VEGF are associated with impeded dendritic cell
function, lowering environmental VEGF concentrations
might beneﬁt this aspect of the antitumor immune
response. In recent phase 3 studies, bevacizumab adminis-
tered in combination with IFNa was more effective than
IFNa alone [66], suggesting that combination therapy
of PD-1–directed agents and VEGF-binding antibodies
merits future study.
Conclusions
Although ﬁrst-generation immunotherapies were of lim-
ited efﬁcacy, they provided proof-of-concept that, in
some patients, the immune balance in the tumor could
be shifted in favor of tumor elimination. Expanding
knowledge and understanding of the immune system’s
role in cancer has revealed multiple mechanisms by which
tumors evade immune destruction. In particular, negative
regulatory pathways involved in the T-cell-mediated
response, including interaction of PD-1 and PD-L1, are
being investigated to determine their role in tumor devel-
opment. Various solid tumors express PD-L1, often
associated with poor prognosis, whereas TILs from these
patients express PD-1 and have impaired antitumor
functionality. Preclinical proof-of-concept for PD-1/
PD-L1 blockade has been demonstrated by many studies:
improvements in various antitumor T-cell functions have
been observed. Several PD-1 and PD-L1-blocking mAbs
have now completed early clinical development with
encouraging activity and safety. The potential for these
agents in the treatment of patients with advanced cancers,
including their incorporation into combination regimens
(e.g., PD-1- plus CTLA-4-blocking antibodies), is signiﬁ-
cant, and further data are eagerly awaited.
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